bullish

JCR Pharma (4552) - Uglyish In-Line Results But a Buyback Opportunity for Someone

277 Views30 Oct 2024 20:58
Contract pharmaceutical smallcap sponsored by Medipal and crossholders JCR Pharma produces ugly H1 results, but they appear "in-line." Guidance is unchanged. And they announce a buyback people can see
What is covered in the Full Insight:
  • Introduction to JCR Pharma's Results
  • Earnings Announcement Details
  • Dividend and Buyback Plans
  • Shareholder Structure and Market Dynamics
  • Long-term Prospects and Investment Summary
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Travis Lundy
Pan-Asia Catalysts/Events
Quiddity Advisors
Japan & Hong KongEquitiesEvent-DrivenQuantitative Analysis
Price Chart(Sign Up to Access)
analytics-chart
x